These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33932913)

  • 1. Corrigendum to 'JAK inhibitors: Current position in treatment strategies for use in inflammatory bowel disease'.
    Hernandez-Rocha C; Vande Casteele N
    Curr Opin Pharmacol; 2021 Jun; 58():68. PubMed ID: 33932913
    [No Abstract]   [Full Text] [Related]  

  • 2. JAK inhibition in inflammatory bowel disease.
    Olivera P; Danese S; Peyrin-Biroulet L
    Expert Rev Clin Immunol; 2017 Jul; 13(7):693-703. PubMed ID: 28164724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum to 'ESPEN guideline: Clinical nutrition in inflammatory bowel disease' [Clinical Nutrition 36 (2) (2016) 321-347].
    Forbes A; Escher J; Hébuterne X; Kłęk S; Krznaric Z; Schneider S; Shamir R; Stardelova K; Wierdsma N; Wiskin AE; Bischoff SC
    Clin Nutr; 2019 Jun; 38(3):1485. PubMed ID: 30955984
    [No Abstract]   [Full Text] [Related]  

  • 4. JAK Inhibition: The Most Promising Agents in the IBD Pipeline?
    Fernández-Clotet A; Castro-Poceiro J; Panés J
    Curr Pharm Des; 2019; 25(1):32-40. PubMed ID: 30950344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
    Coskun M; Salem M; Pedersen J; Nielsen OH
    Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
    Danese S; Argollo M; Le Berre C; Peyrin-Biroulet L
    Gut; 2019 Oct; 68(10):1893-1899. PubMed ID: 31227590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.
    Danese S; Grisham M; Hodge J; Telliez JB
    Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(3):G155-62. PubMed ID: 26608188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.
    Ma C; Lee JK; Mitra AR; Teriaky A; Choudhary D; Nguyen TM; Vande Casteele N; Khanna R; Panaccione R; Feagan BG; Jairath V
    Aliment Pharmacol Ther; 2019 Jul; 50(1):5-23. PubMed ID: 31119766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease.
    Cordes F; Foell D; Ding JN; Varga G; Bettenworth D
    World J Gastroenterol; 2020 Jul; 26(28):4055-4075. PubMed ID: 32821070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK inhibitors and infections risk: focus on herpes zoster.
    Sunzini F; McInnes I; Siebert S
    Ther Adv Musculoskelet Dis; 2020; 12():1759720X20936059. PubMed ID: 32655703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib.
    Nezamololama N; Fieldhouse K; Metzger K; Gooderham M
    Drugs Context; 2020; 9():. PubMed ID: 33240390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease.
    Macaluso FS; Rodríguez-Lago I
    Curr Drug Metab; 2020; 21(4):247-255. PubMed ID: 32156234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
    Yates M; Mootoo A; Adas M; Bechman K; Rampes S; Patel V; Qureshi S; Cope AP; Norton S; Galloway JB
    Arthritis Rheumatol; 2021 May; 73(5):779-788. PubMed ID: 33174384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of Tofacitinib in the treatment of inflammatory bowel disease.
    Nasonov EL; Abdulganieva DI; Fairushina IF
    Ter Arkh; 2019 Mar; 91(2):101-108. PubMed ID: 31094180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
    Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
    Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK/STAT inhibitors for the treatment of atopic dermatitis.
    Rodrigues MA; Torres T
    J Dermatolog Treat; 2020 Feb; 31(1):33-40. PubMed ID: 30703333
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacology, efficacy and safety of JAK inhibitors in Crohn's disease.
    Ma C; Jairath V; Vande Casteele N
    Best Pract Res Clin Gastroenterol; 2019; 38-39():101606. PubMed ID: 31327403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
    Salas A; Hernandez-Rocha C; Duijvestein M; Faubion W; McGovern D; Vermeire S; Vetrano S; Vande Casteele N
    Nat Rev Gastroenterol Hepatol; 2020 Jun; 17(6):323-337. PubMed ID: 32203403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum to 'Role of neurodevelopment involved genes in psychiatric comorbidities and modulation of inflammatory processes in Alzheimer's disease' [J. Neurol. Sci. 370 (November 2016) 162-166].
    Porcelli S; Crisafulli C; Donato L; Calabrò M; Politis A; Liappas I; Albani D; Atti AR; Salfi R; Raimondi I; Forloni G; Papadimitriou GN; De Ronchi D; Serretti A
    J Neurol Sci; 2017 Jan; 372():49. PubMed ID: 28017245
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease.
    Wieringa JW; van der Woude CJ
    Best Pract Res Clin Gastroenterol; 2020; 44-45():101665. PubMed ID: 32359679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.